Ventum Cap Mkts Forecasts Cresco Labs Q1 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Analysts at Ventum Cap Mkts issued their Q1 2025 earnings estimates for Cresco Labs in a research report issued on Wednesday, March 12th. Ventum Cap Mkts analyst A. Semple anticipates that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Ventum Cap Mkts also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.02) EPS and Q4 2025 earnings at ($0.02) EPS.

Separately, Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $3.00.

Cresco Labs Price Performance

Cresco Labs stock opened at $0.75 on Friday. Cresco Labs has a 12-month low of $0.70 and a 12-month high of $2.60. The stock has a market cap of $364.25 million, a P/E ratio of -3.73 and a beta of 1.79. The company has a 50-day moving average price of $0.89 and a 200 day moving average price of $1.20. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.